{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE313nnn/GSE313537/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313537"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"CD4 T cell-derived IL-2 counteracts rapamycin-mediated suppression of CD8 T cell effector differentiation in acute GvHD","description":"Graft-versus-host disease (GvHD) remains a major limitation in the success of allogeneic hematopoietic stem cell transplantation. Rapamycin, an mTOR inhibitor, is used to control alloreactive T cell responses, but its effects on differentiation of donor T cell subsets in vivo are not fully understood. We previously identified two major subsets of alloreactive CD8⁺ T cells that arise during acute GvHD, including TCF1⁺ progenitor-like and Tim-3⁺ terminal effector populations. In this study, we examined how rapamycin influences the activation, circulation, and differentiation states of donor CD8⁺ T cells in murine acute GvHD models, both with and without donor CD4⁺ T cell help. Single-cell RNA sequencing was performed on donor-derived T cells collected from multiple experimental conditions to define the transcriptional programs associated with rapamycin treatment, CD4⁺ T cell involvement, and effector commitment. This dataset enables further investigation of the cellular mechanisms regulating T cell differentiation during GvHD under mTOR inhibition.","dates":{"publication":"2026/06/01"},"accession":"GSE313537","cross_references":{"GSM":["GSM9369830"],"GPL":["30172"],"GSE":["313537"],"taxon":["Mus musculus"]}}